21 March 2019

The burden of liver disease in Europe: The case of Hepatic Encephalopathy - A policy roundtable at the European Parliament

On 26 February 2019, the European Liver Patients’ Association (ELPA) held a policy roundtable entitled ‘The burden of Liver disease in Europe: The case of Hepatic Encephalopathy’ in the European Parliament. The event, co-hosted by the Members of the European Parliament (MEPs) MEP Cristian-Silviu Bușoi (EPP) and MEP Tiemo Wölken (S&D), brought together policymaker and high-level EU stakeholders in liver disease as well as related fields such as brain.
25 January 2019

Preventing NAFLD-NASH epidemic in EU – patients' perspective

Brussels, 10 January 2019
20 December 2018

ELPA Stakeholders' meeting 2018

This year's Stakeholders' meeting was held on 26 November back to back to our EGM and Advisory Board meetings in Ljubljana. Attended by ELPA members and our partners in the field, we have used the opportunity to present our highlights in 2018, as well as the plans for 2019. Traditionally, ELPA has always included its most important stakeholders in the discussion in order to align on activities where possible and detect the possibilities for new collaborations. 
11 December 2018

Report from the Extraordinary general meeting 2018

Brussels, 11 December 2018
10 December 2018

ELPA members choose the new governance

Back in June 2004, 13 patient groups from 10 European and Mediterranean Basin countries met to create the association that will represent all liver patients across Europe – European Liver Patients’ Association.  Since its formal launch in Paris on April 14th 2005 ELPA has been growing continuously and is today counting 37 members from 35 countries. These national chapters share ELPA values and work towards securing that all liver patients are diagnosed in time, are treated with respect, and have equal access to the best standard of medical care - regardless of origin, lifestyle, and type of liver disease.  Every four years, ELPA members among themselves choose patients, professionals and/or experts to represent them in ELPA Governing Board and to advocate for the better of liver patients at the international level. Since 2005 they had the opportunity to do it five times, most recently on 25 November 2018 when ELPA elections for the new president and board members were held. At an extraordinary general meeting, organized back to back with our annual Stakeholders’ and Advisory Board meeting, they have elected Marko Korenjak to succeed Tatjana Reic after her 8 years on this position.
27 July 2018

Highest-risk groups left behind in pursuit of viral hepatitis C elimination in Europe

Results from this years’ Hep-CORE 2018 survey on hepatitis C virus (HCV) micro-elimination are the most recent piece in the puzzle for the ELPA-directed Hep-CORE study.
26 June 2018

“HCC Voices” – the first global survey on people living with hepatocellular carcinoma (HCC)

Although HCC is the sixth most commonly-diagnosed cancer globally, and the second-leading cause of cancer deaths annually, there are very few organisations that focus on HCC patients. As a result, HCC patients may not be receiving adequate support and information about their condition.
13 May 2018

Spring European Testing Week Pilot

This pilot aims to promote wide-scale testing and related activities and seeks to complement the November campaign. This pilot will also focus on identifying barriers that ETW participants experience in implementing integrated testing in different settings across Europe. This pilot will provide another opportunity to promote testing and increase awareness of knowing one's hepatitis/HIV status and assess interest and feasibility of having more than one Testing Week during the year. Additionally, this pilot will focus on integrated testing for hepatitis and HIV.
15 January 2018

Vacancies: Fundraising Manager

30 September 2017

ELPA University IMPACT Programme

10 September 2017

International PBC Day 2017

To support this year’s theme for international PBC day 2017, ‘PBC and Me’, ELPA, along with other 14 associations worldwide, is calling for all the people living with Primary Biliary Cholangitis (PBC) in Europe, to share their experiences of living with the condition on social media. Through sharing stories, ‘PBC and Me’ aims to shine a light on the ‘hidden’ physical and emotional symptoms of the rare auto-immune liver disease. The campaign also aims to address the common misconception that liver diseases are caused by excessive alcohol consumption, which can lead to blame-related stigma for those living with the condition. 
4 September 2017

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

European Association for the Study of the Liver has recently published clinical practice guidelines on the treatment and management of patients with primary biliary cholangitis (PBC).
7 July 2017

UEG issues the Report on Alcohol and Digestive Cancers across Europe

United European Gastroenterology (UEG), with support from the European Association for the Study of the Liver (EASL), the Association of European Cancer Leagues (ECL), the European Liver Patients Association (ELPA), Pancreatic Cancer Europe (PCE), EuropaColon and Eurocare (The Alcohol Policy Alliance), published the report Alcohol and Digestive Cancers Across Europe: Time for Change. Report reveals the data on alcohol consumption across Europe, its direct and indirect impact on digestive cancers and the alarming lack of awareness of the link between alcohol and digestive cancers among members of the public and many healthcare professionals.
3 July 2017

Response to the media coverage of Cochrane study on DAA-Based Treatment of Chronic Hepatitis C

The European Liver Patients’ Association supports unanimous response of hepatitis community to the article “Miracle hepatitis C drugs costing £30k per patient may have no clinical effect”, published on Guardian on 8th of June 2017, referring to the Cochrane Systematic Review on DAA-Based Treatment of Chronic Hepatitis C and their conclusion that such treatment may clear virus from blood, but there is no evidence they prevent harm or save lives.  
8 June 2017

New coalition calls on the EU to take action to eliminate viral hepatitis by 2030, inline with WHO Strategy

Launched at an event in the European Parliament today, the ACHIEVE (short for Associations Collaborating on Hepatitis to Immunize and Eliminate the Viruses in Europe) coalition calls on the EU to take action to eliminate viral hepatitis B and C by 2030 in the WHO European Region, in line with the WHO Global Health Sector Strategy on viral hepatitis, the WHO Europe Action Plan, which build on and the UN Sustainable Development Goals (SDGs).
3 June 2017

Commissioner Carlos Moedas on the importance of research and innovation in fighting NAFLD and NASH

On the occasion of the 1st EU NAFLD - NASH Policy Summit, organized by ELPA on May 31st 2107, Commissioner Carlos Moedas sent a video message on the importance of research and innovation in fighting this disease. 
1 June 2017

NASH and NAFLD - Lifestyle related conditions as the new European public health challenge

Aiming to point out to a still missing and much needed concrete action across Europe to face the next major public health challenge, NASH and NAFLD, leading European and national policy-makers, decision-makers, experts, medical specialists and patient advocacy groups active in liver diseases, met at the first European-wide NASH-NAFLD Policy Summit.
18 May 2017

European Liver Patients’ Association and Norgine continuing to improve the management of hepatic encephalopathy

ELPA and Norgine have launched a patient leaflet to improve the early detection of hepatic encephalopathy, and a patient passport to facilitate conversations with healthcare professionals. Hepatic encephalopathy remains under-diagnosed and under-treated, as many patients and carers are unaware of the signs and symptoms of the disease. In addition, healthcare providers don’t always identify and treat the often subtle symptoms of hepatic encephalopathy, and this can lead to poor patient outcomes and increased hospital admissions.1 Hepatic encephalopathy is a significant complication of advanced chronic liver disease, and occurs in up to 40% of patients or as many as 200,000* people in Europe. 1,2